2023 World Conference on Lung Cancer (Posters)-EP12.01. Osteoblastic Bone Reaction in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Treated with Osimertinib

EP12.01. Osteoblastic Bone Reaction in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Treated with Osimertinib - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the prevalence and details of osteoblastic bone reaction (OBR) in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations treated with osimertinib. OBR refers to an increase in density at the site of bone metastases or the appearance of new sclerotic bone lesions after anticancer treatments, which can be mistaken for disease progression. The study was a retrospective cohort study of patients diagnosed with EGFR-mutant NSCLC with bone metastases who received osimertinib as first-line treatment.<br /><br />A total of 138 patients were included in the study. Of the 51 patients with bone metastases, six were excluded due to lack of CT evaluations or radiation therapy. The median age of the patients was 73 years, and 76% were females. Mixed bone lesions were the most common type of bone metastases at baseline, followed by sclerotic and lytic bone lesions. OBR developed in 82% of the patients, with 94% of patients with sclerotic lesions at baseline developing OBR in sclerotic bone lesions, 76% of patients with lytic lesions developing OBR in lytic bone lesions, and 82% of patients with mixed lesions developing OBR in mixed lesions.<br /><br />The findings of this study suggest that a majority of NSCLC patients receiving osimertinib develop OBR in multiple types of bone metastases. Clinicians should be aware of this phenomenon to avoid misunderstanding OBR as disease progression. Bone metastases are common in advanced NSCLC and can negatively impact patients' quality of life and survival. Understanding the prevalence and characteristics of OBR in patients receiving targeted therapy like osimertinib is important for accurate assessment and management of bone metastases in NSCLC patients.

Asset Subtitle

Kensuke Kanaoka

Meta Tag

Speaker Kensuke Kanaoka

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

osteoblastic bone reaction

non-small cell lung cancer

NSCLC

epidermal growth factor receptor

EGFR mutations

osimertinib

bone metastases

sclerotic bone lesions

lytic bone lesions

mixed bone lesions